Compare stocks

ONWARD Medical N.V. is a medical technology company specializing in spinal cord stimulation therapies aimed at restoring movement, function, and independence for individuals with spinal cord injuries (SCI) and other movement disabilities. Founded in 2014 by researchers at the Swiss Federal Institute of Technology (EPFL), the company is headquartered in Eindhoven, the Netherlands, with additional offices in Lausanne, Switzerland, and Boston, Massachusetts. Its product portfolio includes the ARC-EX System, a non-invasive device designed to enhance upper limb function, and the investigational ARC-IM System, an implantable solution targeting blood pressure stability and other SCI-related symptoms. In 2024, ONWARD Medical secured exclusive rights to develop and commercialize the WIMAGINE Brain-Computer Interface (BCI), positioning the company to integrate thought-driven movement capabilities into its therapies. The company has also received multiple Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for its innovative approaches to SCI treatment.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.